Key result
Review summarizes the epidemiology, genetics, advanced diagnostics, and recent therapeutic developments for PAH.
Why the study?
Accurate early diagnosis and therapy of PAH are necessary because management remains challenging and life expectancy is still suboptimal.
This review summarizes the definition, epidemiology, genetics, diagnosis, and therapy of pulmonary arterial hypertension based on the 6th World Symposia on Pulmonary Hypertension.
Provides clinicians a PAH reference; leaves open prospective validation of emerging diagnostics and therapies.
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and progressive disease, which often leads to premature death. Pulmonary arterial hypertension (PAH, group 1 PH) comprises of diverse diseases that result in similar pathological changes, including the medium-sized pulmonary arteries and pulmonary arterioles characterized by vascular obliteration. The evaluation and diagnosis of PH and PAH were re-defined based on proceedings of the 6th World Symposia on Pulmonary Hypertension (WSPH). Accurate early diagnosis and subsequent therapy of PAH are necessary, as management of this disease is still challenging, and life expectancy is remaining suboptimal. This review task force reflects the multidisciplinary nature of PAH, including the definition, epidemiology, genetics, especially the advanced diagnosis and the therapy development in recent years.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2020) conducted a review in Pulmonary Arterial Hypertension. This review summarizes the definition, epidemiology, genetics, advanced diagnosis, and recent therapy developments for pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: